Syros Pharmaceuticals (NASDAQ: SYRS) reported Q2 EPS of ($1.30), $0.17 worse than the analyst estimate of ($1.13). Revenue for the quarter came in at $2.8 million versus the consensus estimate of $3.5 million.

For earnings history and earnings-related data on Syros Pharmaceuticals (SYRS) click here.